Takeda Pharmaceutical Company Limited – Product Pipeline Review

Global Markets Direct’s, ‘Takeda Pharmaceutical Company Limited – Product Pipeline Review – 2016’, provides an overview of the Takeda Pharmaceutical Company Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Takeda Pharmaceutical Company Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Takeda Pharmaceutical Company Limited

The report provides overview of Takeda Pharmaceutical Company Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Takeda Pharmaceutical Company Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Takeda Pharmaceutical Company Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Takeda Pharmaceutical Company Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Takeda Pharmaceutical Company Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Takeda Pharmaceutical Company Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Takeda Pharmaceutical Company Limited Snapshot 7

Takeda Pharmaceutical Company Limited Overview 7

Key Information 7

Key Facts 7

Takeda Pharmaceutical Company Limited - Research and Development Overview 8

Key Therapeutic Areas 8

Takeda Pharmaceutical Company Limited - Pipeline Review 15

Pipeline Products by Stage of Development 15

Pipeline Products - Monotherapy 16

Pipeline Products - Combination Treatment Modalities 17

Pipeline Products - Partnered Products 18

Pipeline Products - Out-Licensed Products 20

Takeda Pharmaceutical Company Limited - Pipeline Products Glance 22

Takeda Pharmaceutical Company Limited - Late Stage Pipeline Products 22

Takeda Pharmaceutical Company Limited - Clinical Stage Pipeline Products 25

Takeda Pharmaceutical Company Limited - Early Stage Pipeline Products 28

Takeda Pharmaceutical Company Limited - Drug Profiles 33

(alogliptin benzoate + metformin hydrochloride) 33

(alogliptin benzoate + pioglitazone hydrochloride) 35

brentuximab vedotin 38

ceftaroline fosamil 45

ixazomib citrate 48

ramelteon 53

vedolizumab 55

roflumilast 57

(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) 62

azilsartan medoxomil 63

febuxostat XR 65

immune globulin (human) 66

pioglitazone hydrochloride 68

rasagiline mesylate 70

relugolix 71

TAK-003 72

vortioxetine hydrobromide 75

AM-4 78

DSM-265 79

namilumab 81

TAK-063 83

TAK-214 85

TAK-272 87

TAK-850 88

J-591 90

TAK-020 91

TAK-021 92

TAK-058 93

TAK-071 94

TAK-079 95

TAK-653 96

TAK-792 97

TAK-828 98

TAK-831 99

TAK-915 100

TAK-935 101

trelagliptin succinate 102

(plague + small pox) vaccine 104

BTZO-2 105

chikungunya vaccine 106

ELQ-300 107

influenza [strain A/H5N1] vaccine 108

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine 109

mapatumumab 110

Monoclonal Antibody Conjugate to Target c-Ret for Breast Cancer 112

Monoclonal Antibody Conjugate to Target Guanylyl Cyclase C for Oncology 113

Monoclonal Antibody Conjugates for Oncology 114

respiratory syncytial virus (virus like particle) vaccine 115

Rotavirus (virus like particle) vaccine 116

Small Molecule 1 to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression 117

Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease 118

Small Molecule to Activate Glucokinase for Type 2 Diabetes 119

Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain 120

Small Molecule to Agonize GPR52 for Psychiatry Disorders 121

Small Molecule to Antagonize Androgen Receptor for Prostate Cancer 122

Small Molecule to Antagonize CRF1 for CNS Disorders 123

Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia 124

Small Molecule to Antagonize MCHR1 for Obesity 125

Small Molecule to Antagonize Mineralocorticoid Receptor for Hypertension 126

Small Molecule to Antagonize PDGFR and VEGFR-2 for Oncology 127

Small Molecule to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression 128

Small Molecule to Inhibit FAAH for Pain 129

Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease 130

Small Molecule to Inhibit HER2/EGFR for Oncology 131

Small Molecule to Inhibit NET for Stress Urinary Incontinence 132

Small Molecule to Inhibit PKC-Theta 133

Small Molecules for Parkinson's Disease 134

Small Molecules for Visceral Leishmaniasis 135

Small Molecules to Agonize GPR119 for Type II Diabetes 136

Small Molecules to Inhibit Acetyl-CoA Carboxylase for Obesity 137

Small Molecules to Inhibit B-Raf for Oncology 138

Small Molecules to Inhibit CENP-E for Colon Cancer 139

Small Molecules to Inhibit DPP-IV for Type 2 Diabetes 140

Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma 141

Small Molecules to Inhibit MAP2 for Obesity 142

Small Molecules to Inhibit MGAT2 for Metabolic Disorders 143

Small Molecules to Inhibit MMP-13 for Osteoarthritis 144

Small Molecules to Inhibit PARP-1 for Colon Cancer 145

Small Molecules to Inhibit TYK2 146

Stem Cell Therapy for Muscular Dystrophy 147

T-1840383 148

T-3256336 149

TAK-041 150

TAK-480 151

TAK-632 152

Y-443 153

Small Molecule for Undisclosed Indication 154

Small Molecule to Inhibit Arginine Methyltrasferase for Oncology 155

Small Molecule to Inhibit HDAC6 156

Small molecules for Leishmaniasis and Trypanosomiasis 157

Small Molecules for Malaria 158

Small Molecules for Tuberculosis 159

Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 160

Small Molecules to Inhibit FAK for Oncology 161

Small Molecules to Inhibit HER2 and EGFR for Oncology 162

Small Molecules to Inhibit IAP for Oncology 163

Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology 164

Y-142 165

Takeda Pharmaceutical Company Limited - Pipeline Analysis 166

Takeda Pharmaceutical Company Limited - Pipeline Products by Target 166

Takeda Pharmaceutical Company Limited - Pipeline Products by Route of Administration 176

Takeda Pharmaceutical Company Limited - Pipeline Products by Molecule Type 177

Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action 178

Takeda Pharmaceutical Company Limited - Recent Pipeline Updates 188

Takeda Pharmaceutical Company Limited - Dormant Projects 232

Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products 235

Discontinued Pipeline Product Profiles 237

Takeda Pharmaceutical Company Limited - Company Statement 246

Takeda Pharmaceutical Company Limited - Locations And Subsidiaries 247

Head Office 247

Other Locations & Subsidiaries 247

Appendix 257

Methodology 257

Coverage 257

Secondary Research 257

Primary Research 257

Expert Panel Validation 257

Contact Us 257

Disclaimer 258

List of Tables

List of Tables

Takeda Pharmaceutical Company Limited, Key Information 15

Takeda Pharmaceutical Company Limited, Key Facts 15

Takeda Pharmaceutical Company Limited – Pipeline by Indication, 2016 17

Takeda Pharmaceutical Company Limited – Pipeline by Stage of Development, 2016 23

Takeda Pharmaceutical Company Limited – Monotherapy Products in Pipeline, 2016 24

Takeda Pharmaceutical Company Limited – Combination Treatment Modalities in Pipeline, 2016 25

Takeda Pharmaceutical Company Limited – Partnered Products in Pipeline, 2016 26

Takeda Pharmaceutical Company Limited – Partnered Products/ Combination Treatment Modalities, 2016 27

Takeda Pharmaceutical Company Limited – Out-Licensed Products in Pipeline, 2016 28

Takeda Pharmaceutical Company Limited – Out-Licensed Products/ Combination Treatment Modalities, 2016 29

Takeda Pharmaceutical Company Limited – Pre-Registration, 2016 30

Takeda Pharmaceutical Company Limited – Filing rejected/Withdrawn, 2016 31

Takeda Pharmaceutical Company Limited – Phase III, 2016 32

Takeda Pharmaceutical Company Limited – Phase II, 2016 33

Takeda Pharmaceutical Company Limited – Phase I, 2016 34

Takeda Pharmaceutical Company Limited – Phase 0, 2016 35

Takeda Pharmaceutical Company Limited – IND/CTA Filed, 2016 36

Takeda Pharmaceutical Company Limited – Preclinical, 2016 37

Takeda Pharmaceutical Company Limited – Discovery, 2016 40

Takeda Pharmaceutical Company Limited – Pipeline by Target, 2016 174

Takeda Pharmaceutical Company Limited – Pipeline by Route of Administration, 2016 184

Takeda Pharmaceutical Company Limited – Pipeline by Molecule Type, 2016 185

Takeda Pharmaceutical Company Limited – Pipeline Products by Mechanism of Action, 2016 186

Takeda Pharmaceutical Company Limited – Recent Pipeline Updates, 2016 196

Takeda Pharmaceutical Company Limited – Dormant Developmental Projects,2016 240

Takeda Pharmaceutical Company Limited – Discontinued Pipeline Products, 2016 243

Takeda Pharmaceutical Company Limited, Other Locations 255

Takeda Pharmaceutical Company Limited, Subsidiaries 255

List of Figures

List of Figures

Takeda Pharmaceutical Company Limited – Pipeline by Top 10 Indication, 2016 17

Takeda Pharmaceutical Company Limited – Pipeline by Stage of Development, 2016 23

Takeda Pharmaceutical Company Limited – Monotherapy Products in Pipeline, 2016 24

Takeda Pharmaceutical Company Limited – Combination Treatment Modalities in Pipeline, 2016 25

Takeda Pharmaceutical Company Limited – Partnered Products in Pipeline, 2016 26

Takeda Pharmaceutical Company Limited – Out-Licensed Products in Pipeline, 2016 28

Takeda Pharmaceutical Company Limited – Pipeline by Top 10 Target, 2016 174

Takeda Pharmaceutical Company Limited – Pipeline by Route of Administration, 2016 184

Takeda Pharmaceutical Company Limited – Pipeline by Molecule Type, 2016 185

Takeda Pharmaceutical Company Limited – Pipeline Products by Top 10 Mechanism of Action, 2016 186

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports